GlassScriptPhysician profile
Thomas K Gaide
NPI 1447301791
$2,953.40
in general payments reported to CMS, 2019-2025
33 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $427 · 2021: $504 · 2022: $633 · 2023: $375 · 2024: $342 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $911.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $445.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $412.61 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $254.32 | 2019-2025 | |
| Abbvie INC. | $241.52 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $220.72 | 2020-2025 | Airsupra, Breztri |
| E.R. Squibb & Sons, L.L.C. | $152.33 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $124.10 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.53 | 2019-2022 | |
| Glaxosmithkline, LLC. | $102.29 | 2019-2025 | Arexvy, Shingrix |
| Eisai INC. | $80.66 | 2020-2021 | |
| Lilly USA, LLC | $76.24 | 2021-2024 | Amyvid, Trulicity, Mounjaro |
| Astellas Pharma US INC | $69.80 | 2019-2023 | Myrbetriq, Veozah |
| Merck Sharp & Dohme LLC | $61.46 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.98 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $51.67 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $48.42 | 2022 | |
| Allergan, INC. | $45.71 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $45.45 | 2020-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.17 | 2022 | |
| Aimmune Therapeutics, INC. | $39.07 | 2025 | Zenpep |
| Biohaven Pharmaceuticals, INC. | $36.42 | 2021 | |
| Exact Sciences Corporation | $33.10 | 2023-2024 | Cologuard Collection Kit |
| Ethicon US, LLC | $27.46 | 2019 | |
| Phadia US INC. | $24.88 | 2023 | Immunocap |
| Sumitomo Pharma America, INC. | $23.92 | 2023 | Gemtesa |
| Inspire Medical Systems, INC. | $21.97 | 2023 | Inspire |
| Daiichi Sankyo INC. | $20.93 | 2021 | |
| Mylan Specialty L.P. | $15.84 | 2022 | |
| Strongbridge US INC. | $14.68 | 2020 | |
| Boston Scientific Corporation | $14.60 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.03 | 2021 | |
| Cook Medical LLC | $13.24 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gaide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.